Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...

For AML, the denominator for reporting should be based off of total viable, nucleated cells and for ALL, either total viable, nucleated cells or mononuclear cells (which eliminate granulocytes from ...

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. A new study by ...

Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL We retrospectively analyzed 473 adult patients with ...

The BD OneFlow™ AML/MDS Panel is intended for qualitative flow-cytometric immunophenotyping of mature and immature hematopoietic cells populations (lymphoid and myeloid lineages) in bone marrow and ...

By late 2024, the phase 2 KOMET-001 trial had enrolled 112 patients in North America and Europe—all with relapsed/refractory NPM1-mutated AML. Patients received ziftomenib 600 mg orally once a day as ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...